Leukos Biotech
New treatments for Acute Myeloid Leukaemia and other haematological malignancies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €200k | Debt | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 94 % | (1 %) | 63 % | (40 %) | - | 245 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 7 % | 3 % | (4 %) | 28 % | 20 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 5 % | 1 % | (8 %) | 21 % | 14 % | 1646 % | (97 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Leukos Biotech is a biopharmaceutical company dedicated to developing innovative treatments and diagnostic tools for various types of tumors, including both blood-related (hematological) and solid tumors. The company’s primary focus is on advancing its lead candidate, LB208, which aims to provide new therapeutic options for cancer patients.
Leukos Biotech operates in the highly competitive biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies as its main clients. The company’s business model revolves around research and development (R&D) of new drugs and diagnostic methods. By identifying new oncological targets, such as the serotonin receptor, Leukos Biotech aims to create proprietary treatments that can be licensed or sold to larger pharmaceutical companies.
Revenue generation for Leukos Biotech primarily comes from licensing agreements, partnerships, and potential sales of its developed treatments and diagnostic tools. By validating proprietary monoclonal antibodies (mABs) as biomarkers, the company enhances its diagnostic capabilities, providing valuable tools for the prognosis and diagnosis of cancer patients.
Leukos Biotech is a spin-off from the Josep Carreras Leukaemia Research Institute, which underscores its strong foundation in cancer research. The company boasts a multidisciplinary and enthusiastic team committed to bringing new cures to market, leveraging their expertise to tackle both solid and hematological malignancies.
Keywords: biopharmaceutical, cancer treatment, diagnostic tools, tumors, hematological, solid tumors, LB208, oncology, biomarkers, R&D.